Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.22/19425 |
Resumo: | Herein the quantitative synthesis of eight new mono- and dianionic Organic Salts and Ionic Liquids (OSILs) from alendronic acid (ALN) is reported by following two distinct sustainable and straightforward methodologies, according to the type of cation. The prepared ALN-OSILs were characterized by spectroscopic techniques and their solubility in water and biological fluids was determined. An evaluation of the toxicity towards human healthy cells and also human breast, lung and bone (osteosarcoma) cell lines was performed. Globally, it was observed that the monoanionic OSILs showed lower toxicity than the corresponding dianionic structures to all cell types. The highest cytotoxic effect was observed in OSILs containing a [C2OHMIM] cation, in particular [C2OHMIM][ALN]. The latter showed an improvement in IC50 values of ca. three orders of magnitude for the lung and bone cancer cell lines as well as fibroblasts in comparison with ALN. The development of OSILs with high cytotoxicity effect towards the tested cancer cell types, and containing an anti-resorbing molecule such as ALN may represent a promising strategy for the development of new pharmacological tools to be used in those pathological conditions. |
id |
RCAP_816ed2afd7f5ecbae6385d4f26b4969a |
---|---|
oai_identifier_str |
oai:recipp.ipp.pt:10400.22/19425 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Alendronic Acid as Ionic Liquid: New Perspective on OsteosarcomaAlendronic acidActive Pharmaceutical IngredientAPI-OSILsAnticancer drugsIonic liquidsHerein the quantitative synthesis of eight new mono- and dianionic Organic Salts and Ionic Liquids (OSILs) from alendronic acid (ALN) is reported by following two distinct sustainable and straightforward methodologies, according to the type of cation. The prepared ALN-OSILs were characterized by spectroscopic techniques and their solubility in water and biological fluids was determined. An evaluation of the toxicity towards human healthy cells and also human breast, lung and bone (osteosarcoma) cell lines was performed. Globally, it was observed that the monoanionic OSILs showed lower toxicity than the corresponding dianionic structures to all cell types. The highest cytotoxic effect was observed in OSILs containing a [C2OHMIM] cation, in particular [C2OHMIM][ALN]. The latter showed an improvement in IC50 values of ca. three orders of magnitude for the lung and bone cancer cell lines as well as fibroblasts in comparison with ALN. The development of OSILs with high cytotoxicity effect towards the tested cancer cell types, and containing an anti-resorbing molecule such as ALN may represent a promising strategy for the development of new pharmacological tools to be used in those pathological conditions.This work was supported by the Associate Laboratory for Green Chemistry LAQV which is financed by national funds from FCT/MCTES (UIDB/50006/2020). The authors also thank Fundação para a Ciência e Tecnologia for the projects PTDC/QUI-QOR/32406/2017, PEst-C/LA0006/2013 and RECI/BBBBQB/0230/2012), as well as one contract under Investigador FCT (L. C. Branco). The authors also acknowledge the Solchemar company.MDPIRepositório Científico do Instituto Politécnico do PortoTeixeira, SóniaSantos, Miguel M.Fernandes, Maria H.Costa-Rodrigues, JoaoBranco, Luís C.2022-01-12T11:40:49Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.22/19425engTeixeira, S., Santos, M. M., Fernandes, M. H., Costa-Rodrigues, J., & Branco, L. C. (2020). Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma. Pharmaceutics, 12(3), Artigo 3. https://doi.org/10.3390/pharmaceutics120302931999-492310.3390/pharmaceutics12030293info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-20T01:54:49Zoai:recipp.ipp.pt:10400.22/19425Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:39:22.638658Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma |
title |
Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma |
spellingShingle |
Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma Teixeira, Sónia Alendronic acid Active Pharmaceutical Ingredient API-OSILs Anticancer drugs Ionic liquids |
title_short |
Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma |
title_full |
Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma |
title_fullStr |
Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma |
title_full_unstemmed |
Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma |
title_sort |
Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma |
author |
Teixeira, Sónia |
author_facet |
Teixeira, Sónia Santos, Miguel M. Fernandes, Maria H. Costa-Rodrigues, Joao Branco, Luís C. |
author_role |
author |
author2 |
Santos, Miguel M. Fernandes, Maria H. Costa-Rodrigues, Joao Branco, Luís C. |
author2_role |
author author author author |
dc.contributor.none.fl_str_mv |
Repositório Científico do Instituto Politécnico do Porto |
dc.contributor.author.fl_str_mv |
Teixeira, Sónia Santos, Miguel M. Fernandes, Maria H. Costa-Rodrigues, Joao Branco, Luís C. |
dc.subject.por.fl_str_mv |
Alendronic acid Active Pharmaceutical Ingredient API-OSILs Anticancer drugs Ionic liquids |
topic |
Alendronic acid Active Pharmaceutical Ingredient API-OSILs Anticancer drugs Ionic liquids |
description |
Herein the quantitative synthesis of eight new mono- and dianionic Organic Salts and Ionic Liquids (OSILs) from alendronic acid (ALN) is reported by following two distinct sustainable and straightforward methodologies, according to the type of cation. The prepared ALN-OSILs were characterized by spectroscopic techniques and their solubility in water and biological fluids was determined. An evaluation of the toxicity towards human healthy cells and also human breast, lung and bone (osteosarcoma) cell lines was performed. Globally, it was observed that the monoanionic OSILs showed lower toxicity than the corresponding dianionic structures to all cell types. The highest cytotoxic effect was observed in OSILs containing a [C2OHMIM] cation, in particular [C2OHMIM][ALN]. The latter showed an improvement in IC50 values of ca. three orders of magnitude for the lung and bone cancer cell lines as well as fibroblasts in comparison with ALN. The development of OSILs with high cytotoxicity effect towards the tested cancer cell types, and containing an anti-resorbing molecule such as ALN may represent a promising strategy for the development of new pharmacological tools to be used in those pathological conditions. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020 2020-01-01T00:00:00Z 2022-01-12T11:40:49Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.22/19425 |
url |
http://hdl.handle.net/10400.22/19425 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Teixeira, S., Santos, M. M., Fernandes, M. H., Costa-Rodrigues, J., & Branco, L. C. (2020). Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma. Pharmaceutics, 12(3), Artigo 3. https://doi.org/10.3390/pharmaceutics12030293 1999-4923 10.3390/pharmaceutics12030293 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
MDPI |
publisher.none.fl_str_mv |
MDPI |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1817552364473679872 |